



15 May 2014

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

cyclomedica
technegas
cyclopet

Cyclopharm Ltd
ABN 74 116 931 250
Bldg 75 Business & Technology Park
New Illawarra Road
Lucas Heights NSW 2234 Australia
POB 350 Menai Central NSW 2234
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

Chairman Reinstated

On 23rd October 2013, we advised that the Chairman Mr Vanda Gould was standing aside temporarily from the role of Chairman, to defend charges in relation to ongoing taxation matters. Mr Gould has consistently maintained his innocence of any wrongdoing in relation to these charges, and elected to remain on the Board as a non-executive director, whilst these matters were being resolved. Mr David Heaney was appointed interim Chairman until further notice.

We are pleased to advise that on 13th May 2014, the Commonwealth Director of Prosecutions withdrew all charges against Mr Gould, and the Board has again reinstated Mr Gould to the position of Chairman, effective immediately. This has been a challenging time for Mr Gould as a result of the negative publicity surrounding the charges, and he can now begin the process of restoring his credibility.

The Board thanks Mr Heaney for undertaking the role of Chairman during this difficult period

For more information, please contact either:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411



Background

Cyclopharm Limited

Cyclopharm is a radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes.

Cyclopharm achieves this objective through the provision of radiopharmaceutical products, Technegas (for lung imaging) and Molecular Imaging / PET radiopharmaceuticals (used in cancer, brain and cardiac imaging). Our customers are nuclear medicine departments located within hospitals and clinics.

Technegas

The Technegas technology is a structured ultra-fine dispersion of radioactive labeled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700°C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for the superior diagnosis of pulmonary emboli (blood clots in the lungs).

Positron Emission Tomography (PET)

PET radiopharmaceuticals target specific tissues / organs, concentrate there, and the attached radioisotope emits radiation, which is then detected by a PET or PET / CT gamma (collectively PET camera). These imaging modalities help physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease at a metabolic level. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed at a much earlier stage.